Publication | Open Access

Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study

Tumor ImmunologyCancer ImmunosurveillanceMelanomaImmunologyPathologyPeripheral BloodClinical PhaseTherapeutic VaccineImmunomodulationAnti-melanoma Lytic ActivityImmunotherapyMedicine